US/UK/Canada

Share

Contacts

  • Sprint Bioscience
    NOVUM 141 57 Huddinge Sweden
    +46-8-411 44 55
    http://www.sprintbioscience.com

    • Quotes

    Inhibiting TREX1 is a unique approach with great potential to enhance the effect of several current therapies. Many modern cancer drugs depend on the immune system being able to identify the cancer cells, and with our TREX1 inhibitors, we have identified a way to stop the cancer cells' ability to hide from the immune system. We have now reached a strong competitive position in the program's development and look forward to discussions with potential partners.
    Martin Andersson, head of research at Sprint Bioscience
    We have once again been able to identify a target protein that constitutes a very attractive starting point for a new drug program. The ambition is to influence the microenvironment of the tumors so that the growth of cancer cells is inhibited and the body's immune system can more easily fight them. We will in a time- and resource-efficient way drive the project to a point where it can dock into an international pharmaceutical company's portfolio and be taken further to clinic development towards the market and cancer patients who need new treatment option
    Erik Kinnman, CEO, Sprint Bioscience
    Immunotherapy is showing tremendous benefits in cancer but unfortunately the majority of cancer patients do not respond to current immunotherapy approaches. There is therefore a great need to increase the tumor’s susceptibility of attack from the immune system, and here inhibitors of the protein Vps34 may play an important role.
    Dr. Ravi Amaravadi, MD Associate Professor of Medicine and Sprint Bioscience scientific advisor,
    We thank Anders Åberg for all the fantastic work that has led to Sprint Bioscience becoming the high-quality company it is today.
    Rune Nordlander, Chairman of Sprint Bioscience
    We are very happy to have entered into this agreement with LG Chem Life Sciences Company, a perfect partner to further develop this program.
    Dr. Anders Åberg, CEO of Sprint Bioscience
    Leveraging Sprint Bioscience’s expertise in fragment-based drug discovery capability and LG Chem Life Sciences’ capability in pharma-ceutical development, we aim to accelerate bringing new treatment options for NASH and metabolic syndrome.
    Dr. Jeewoong Son, President of LG Chem Life Sciences Company
    Patent protection gives us an edge over others in the field
    Anders Åberg, CEO, Sprint Bioscience
    We know from our contacts with the pharmaceutical industry that immuno-oncology is an area where demand for new projects is high
    Anne-Marie Wenthzel, Head of Business Development at Sprint Bioscience
    We are really happy to have closed a deal with a company with world leading expertise in tumor metabolism biology. It will increase the chances to develop a drug to the benefit for cancer patients.
    Dr Anders Åberg, CEO of Sprint Bioscience
    To combine frontline research with our platform for fast and resource efficient development of drugs, together with the Lundberg Laboratory for Diabetes Research, provides great opportunities for Sprint Bioscience to develop a new cure for T2D
    Dr Anders Åberg, CEO Sprint Bioscience
    I look forward to working with Sprint Bioscience in this project. Together, we will develop inhibitors that affect a central mechanism for insulin resistance
    Dr Margit Mahlapuu, The Lundberg Laboratory for Diabetes Research
    We are very happy to have entered into this agreement for one of our tumor metabolism projects. We are convinced that Bayer is a perfect partner to further develop this program.
    Anders Åberg, CEO, Sprint Bioscience
    We are looking forward to expanding our portfolio in this area through the agreement with Sprint Bioscience. This early research program has the potential to lead to new treatment options for cancer patients.
    Professor Andreas Busch, Head of Global Drug Discovery and member of the Executive Committee of Bayer HealthCare
    Pick a time period -
    Tags ( Active)

    BioStock: Sprint Bioscience CEO comments on deal potential

    The LSX Nordic Partnering and Investor Congress is in full swing in Copenhagen, and Sprint Bioscience is one of the attending companies. BioStock met with CEO Johan Emilsson and picked his brain on the market climate, the potential of preclinical partnering, and the development of the TREX-1 program.See the full interview at biostock.se : https://www.biostock.se/en/2024/10/sprint-bioscience-ceo-comments-on-deal-potential/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

    BioStock: Sprint Bioscience focuses on developing internal programs and partnering

    When research company Sprint Bioscience publishes its report for the third quarter, the focus is on development of the internal pharmaceutical programs and new partnerships. The company had a busy schedule at BioEurope, which took place this week in Leipzig, Germany, and it continued to see great interest in the VADA and DISA programs. BioStock talked to CEO Erik Kinnman about partnerships, the upcoming rights issue and what lies ahead.Read the full article about the Sprint Biosciences latest quarter at biostock.se/en: https://www.biostock.se/en/2022/10/sprint-bioscience-focuses-on-

    BioStock: Sprint Bioscience increases innovation power

    Huddinge-based Sprint Bioscience has a long-standing collaboration with Associate Professor Julian Walfridsson to find new target proteins that may be relevant in the treatment of acute myeloid leukemia. Last autumn, the project was awarded a research grant of 2.5 MSEK and now the collaboration is further expanded.Read the full article at biostock.se:https://www.biostock.se/en/2022/05/sprint-bioscience-increases-innovation-power/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

    BioStock: Sprint Bioscience maintains focus on developing the portfolio

    With the activities for 2022 in full swing, Sprint Bioscience publishes the report for the year’s first quarter where we can note a continued focus on developing the programs in the portfolio. The company will begin presenting the latest internal program in the portfolio to potential partners and a scientific council has been appointed to support the future development. BioStock contacted the company’s CEO Erik Kinnman to get his thoughts on the first quarter.Read the full article at biostock.se:https://www.biostock.se/en/2022/05/sprint-bioscience-maintains-focus-on-developing-the-

    BioStock: Sprint Bioscience launches NIMA at BIO International

    It has been a little more than six months since Huddinge-based Sprint Bioscience announced its latest development project NIMA. Now the company chooses to shed some more light on the program, revealing the the target protein. The official launch will be at BIO International, which this year will be held in San Diego June 13-16. BioStock contacted Martin Andersson, CSO at Sprint Bioscience, to find out more.Read the full article at biostock.se:https://www.biostock.se/en/2022/05/sprint-bioscience-launches-nima-at-bio-international/This is a press release from BioStock - Connecting

    BioStock: Sprint Biosciences CSO comments on further VADA validation

    After last year’s out-licensing of Vps34, the focus is now on the next program in Sprint Bioscience’s portfolio. The VADA program has come the furthest and new research findings provide further validation to the target protein VRK1. In addition to a better understanding of the role the protein plays in cancer, the results also point to a broadened commercial potential for VADA. BioStock contacted Sprint Bioscience’s Head of Research Martin Andersson to find out more.Read the full article at biostock.se:https://www.biostock.se/en/2022/04/sprint-biosciences-cso-comments-on-further-vada-

    BioStock: Sprint Bioscience invests to expand portfolio and number of deals

    Huddinge-based Sprint Bioscience has had an eventful 2021 to say the least. In the face of the success of the past year, the company is now taking concrete steps to be able to increase the pace even further. The goal for the company is to broaden its portfolio of preclinical drug programmes in cancer and increase the number of programmes licensed to partners, thus increasing the potential for multiple revenue streams.Read the full article at biostock.se:https://www.biostock.se/en/2021/12/sprint-bioscience-invests-to-expand-portfolio-and-number-of-deals/This is a press release from

    BioStock: Strengthening quarter for Sprint Bioscience

    For Sprint Bioscience the third quarter was an intense and news-dense period. Thanks to a licensing agreement and a rights issue, the company now finds itself in its strongest financial position to date and ready to take the next step in its development. BioStock contacted CEO Erik Kinnman to get his view on the past quarter and on the future.Read the full article at biostock.se:https://www.biostock.se/en/2021/10/strengthening-quarter-for-sprint-bioscience/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

    BioStock: Sprint Bioscience receives research grant

    Sprint Bioscience is constantly looking for highly interesting starting points for preclinical drug development projects, primarily in the field of cancer. Through a collaboration with Dr Julian Walfridsson at Karolinska Institutet, the company will identify new target proteins suitable for the treatment of blood cancer. The project has now been rewarded with a 2.5 MSEK research grant from the Swedish Foundation for Strategic Research.Read the full article at biostock.se:https://www.biostock.se/en/2021/10/sprint-bioscience-gets-research-grant/This is a press release from BioStock -

    BioStock: Sprint Bioscience initiates marketing of the DISA-program

    The preclinical development experts at Sprint Bioscience started the second half of the year by signing the company’s largest licensing agreement to date in a deal concerning drug candidate Vps34. The company is now initiating marketing for the next project in line. BioStock spoke to the company’s Chief Scientific Officer, Martin Andersson, to find out more about the project.Read the full article at biostock.se:https://www.biostock.se/en/2021/09/sprint-bioscience-initiates-marketing-of-the-disa-program/This is a press release from BioStock - Connecting Innovation & Capital. https://www.

    Sprint Bioscience initiates marketing of an additional cancer drug program

    Sprint Bioscience announces today that it is starting to market the DISA program to potential partners and, following a series of research advances, reveals the cancer drug program's target protein, TREX1. The goal of the program, currently in the preclinical phase, is to develop drugs that inhibit the protein TREX1 in order to enhance the effect of immuno-oncological therapy, radiation therapy and chemotherapy in the treatment of cancer. The company will initiate discussions with potential partners in connection with the BioEurope conference in October.Cancer cells often have elevated

    BioStock: A new cancer project in Sprint Bioscience’s portfolio

    In connection with the rights issue this summer, the biotechnology company Sprint Bioscience promised further investments in expanding the development portfolio. Now, about a week after completing the issue, the company has announced NIMA, a cancer project that targets a tumour’s microenvironment to affect the cancer’s ability to grow while at the same time making it easier for the immune system to attack it directly.Read the full article at biostock.se:https://www.biostock.se/en/2021/09/a-new-cancer-project-in-sprint-biosciences-portfolio/This is a press release from BioStock -

    Sprint Bioscience adds new cancer drug program to its project portfolio

    Sprint Bioscience AB (publ) announces today that the company is broadening its pipeline with an additional drug program for the treatment of solid tumors. The program goes by the program name NIMA and aims to develop drugs to inhibit a naturally occurring protein that is associated with poor survival in several different forms of cancer.An important aspect of the development of a tumor is that the cancer cells can affect their environment to facilitate the growth of the tumor. This environment is called the tumor microenvironment and differs from the environment around the healthy cells in

    Sprint Bioscience licenses the cancer drug program Vps34 to Deciphera Pharmaceuticals

    Sprint Bioscience AB (publ) announces today that the company has licensed its cancer drug program Vps34 to the US pharmaceutical company Deciphera Pharmaceuticals. The license agreement covers exclusive global rights to the program. The agreement has a total potential value of up to USD 277 million, plus additional tiered percentage royalties ranging from the mid-single-digits to the low-double-digits on the sales of a future drug from the program, if approved. On signing of the agreement, Sprint Bioscience will receive an upfront payment of USD 4 million, which will be entered into the

    BioStock: Sprint Bioscience’s new CEO on the business model and cancer projects

    This February, Stockholm-based drug developer Sprint Bioscience announced that Erik Kinnman will take over as CEO of the company. The company specialises in preclinical development of small molecules within oncology. In an interview with BioStock, Kinnman talks more about his background, his view on the company and the business model.Read the full article at biostock.se: https://www.biostock.se/en/sprint-biosciences-new-ceo-on-the-business-model-and-cancer-projects/This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se

    BioStock: Directed issue of 20.7 MSEK strengthens cash position for Sprint Bioscience

    Stockholm-based Sprint Bioscience, which conducts early preclinical drug development primarily targeting cancer, announced on Thursday morning that it had raised 20.7 MSEK in a share issue directed at a group of existing and external investors. BioStock has contacted the company’s CEO Erik Kinnman to find out more about what it means for the company.Read the full article at biostock.se:https://www.biostock.se/en/directed-issue-of-20-7-msek-strengthens-cash-position-for-sprint-bioscience/This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se

    BioStock: Great interest in Sprint Bioscience at BIO-Europe

    Swedish biotech company Sprint Bioscience carries out preclinical development in cancer, with the aim of early outlicensing of its pharmaceutical projects. The pharmaceutical industry is constantly looking for exciting new projects, with a great example being last week´s digital edition of the partnering conference BIO-Europe Spring, where there was great interest in company’s projects. BioStock spoke to the company’s Chief Scientific Officer Martin Andersson and Business Development Manager Anne-Marie Wenthzel who commented on the conference.Read the full article at biostock.se:https://

    Sprint Bioscience appoints Erik Kinnman as new CEO

    Sprint Bioscience AB (publ) announces today that Erik Kinnman has been appointed new CEO of the company. He has 25 years of experience from leading positions in the pharmaceutical and biotechnology industry. Erik Kinnman will take up the role on March 1 and succeed Charlotte Leife, who has been acting CEO since September 1, 2021.Erik Kinnman was between 2016 and January 2021 CEO of Abliva AB (formerly Neurovive), a biotechnology company listed on Nasdaq Stockholm's Main Market. Prior to that, he held senior positions at AstraZeneca and SOBI and was also active as a financial analyst at

    Independent validation of the concept behind Sprint Biosciences' drug project Vps34

    Newly published results from three independent research groups support the concept behind Sprint Biosciences' drug project Vps34. The articles confirm that autophagy in tumors makes it easier for cancer cells to escape attacks from the body's immune system. This external validation leads to an increased interest in the Vps34 project in the pharmaceutical industry and strengthens Sprint Biosciences' position in discussions with potential licensees.Sprint Bioscience were the first to describe how autophagy can promote tumor development in an article published in Science Advances earlier this

    Sprint Bioscience announces the identity of the target protein in the wholly-owned project VADA

    Sprint Bioscience today announces that after a series of preclinical research advances in the VADA project, it has been decided to publish the project's target protein. The goal is to develop drug substances that inhibit the protein vaccinia-related kinase 1 (VRK1) in order to enhance the effects of immuno-oncology therapy, radiation therapy and chemotherapy. The company believes that this approach paves the way for a unique position in the market for innovative drug projects and will now initiate contacts with potential partners.The new target protein VRK1 acts by regulating the activity

    Sprint Bioscience publishes scientific study with new positive data from the Vps34 program

    Sprint Bioscience AB (publ.) (Sprint Bioscience) today announces that a new scientific study with positive data concerning the company's lead compound SB02024 has been published in Science Advances. The research results show that SB02024 activates the immune system in tumors in malignant melanoma and colorectal cancer. Sprint Bioscience is thus first in the world to demonstrate that inhibition of the Vps34 protein and the autophagy of tumor cells can be an important part of future immunological treatments.Autophagy is the cell's processes for breaking down and recycling itself. It is

    Sprint Bioscience appoints Jessica Martinsson as acting CEO after CEO Anders Åberg announces his resignation

    Sprint Bioscience AB (publ.) (Sprint Bioscience) today announced that the Board has appointed Jessica Martinsson as acting CEO. Jessica Martinsson, who has held the position of operational manager, succeeds Anders Åberg, who has chosen to leave his post after 10 years as CEO.Anders Åberg co-founded Sprint Bioscience and during his ten years as CEO has led the work of building an effective research and development organization that has been able to attract a number of international partners. In recent years, the company has established three license agreements with global pharmaceutical

    Sprint Bioscience Collaborate with LG Chem to Develop Novel Treatments for NASH and Metabolic Disorders

    Sprint Bioscience AB (publ.) and LG Chem Life Sciences Company have entered into a collaboration and license agreement for the research, development, and commercialization of Sprint Bioscience’s discovery stage program for NASH and metabolic disorders.Sprint Bioscience AB (publ) (Sprint Bioscience) and LG Chem Life Sciences Company (LG Chem) have entered into a collaboration and license agreement for the research, development, and commercialization of drug candidates. Under the agreement, Sprint Bioscience licenses a discovery stage program to LG Chem for potential treatments of NASH and

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Rss